Immunohistochemical evaluation of cyclin D1 in breast cancer

Croatian Medical Journal

Volumn 46, Issue 3, 2005, Pages 382-388

  Bilalović, Nurija ^a   Vranić, Semir ^a   Bašić, Hiba ^a   Tatarević, Aida ^a   Selak, Ivan ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER SIZE; CLINICAL ARTICLE; CORRELATION ANALYSIS; EVALUATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL RECORD; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; RELAPSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLIN D1; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN;

EID: 18844367134     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Esteva FJ, Hortobagyi CN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6:109-18.
2. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark CM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-78.
3. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002;4:14-7.
4. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004;9:95-104.
5. Ewen ME, Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med. 2004;10:158-62.
6. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene. 1994;9:707-18.
7. al Saati T, Clamens S, Cohen-Knato E, Faye JC, Prats H, Coindre JM, et al. Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer. 1993;55:651-4.
8. Traish AM, Wotiz HH. Monoclonal and polyclonal antibodies to human progesterone receptor peptide-(533-547) recognize a specific site in unactivated (8S) and activated (4S) progesterone receptor and distinguish between intact and proteolyzed receptors. Endocrinology. 1990;127:1167-75.
9. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gaiter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol. 1990;137:225-32.
10. Tavassoli F, Devilee P, editors. World Health Organization Classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
11. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716-21.
12. Nakopoulou L, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, etal. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod Pathol. 2002;15:26-34.
13. Chasle J, Delozier T, Denoux Y, Marnay J, Michels JJ. Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas - a preliminary study. Eur J Cancer. 2003;39:1363-9.
14. Zhang SY, Caamano J, Cooper F, Cuo X, Klein-Szanto AJ. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol. 1994;102:695-8.
15. Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int. 2003;53:74-80.
16. Naidu R, Wahab NA, Yadav MM, Kutty MK. Expression and amplification of cyclin Dl in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep. 2002;9:409-16.
17. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer. 2004;90:1942-8.
18. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res. 1999;5:2069-76.
19. Han EK, Ng SC, Arber N, Begemann M, Weinstein IB. Roles of cyclin D1 and related genes in growth inhibition, senescence and apoptosis. Apoptosis. 1999;4:213-9.
20. Massague J. G1 cell-cycle control and cancer. Nature. 2004;432:298-306.
21. Lin HM, Lee YJ, Li G, Pestell RC, Kim HR. Bcl-2 induces cyclin D1 promoter activity in human breast epithelial cells independent of cell anchorage. Cell Death Differ. 2001;8:44-50.
22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
23. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004;204:93-100.
24. Barnes DM, Cillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat. 1998;52:1-15.
25. Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR, SloaneJP. Immunodetectable cyclin D(1) is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer. 2001;84:1064-9.
26. de Jong JS, van Diest PJ, Michalides RJ, Baak JP. Concerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas. Mol Pathol. 1999;52:78-83.
27. Ding SL, Sheu LF, Yu JC, Yang TL, Chen B, Leu FJ, et al. Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J Biomed Sci. 2004;11:911-9.
28. Fu M, Wang C, Li Z, Sakamaki T, Pestell RC. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439-47.
29. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem. 1997;272:10882-94.
30. Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Sorgo R, et al. Estrogens and progesterone promote persistent CCNDI gene activation during C1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol. 2004;24:7260-74.
31. Man S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, et al. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol Rep. 2003;10:141-4.
32. Hui R, Finney CL, Carroll JS, Lee CS, Musgrove EA, Sutherland RL. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res. 2002;62:6916-23.